The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "Tofacitinib"

Search results for: Tofacitinib

The Effect of Tofacitinib on Live Vaccine Responses

February 26, 2016 • By Richard Quinn

New research indicates that vaccination for the herpes zoster virus in patients with rheumatoid arthritis starting tofacitinib appears to be both safe and useful. Rheumatologists may want to check the patient’s pre-existing immunity status prior to administering the vaccine…... [Read More]

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis

Tofacitinib Decreases Inflammation in Early RA

February 12, 2016 • By Michele B. Kaufman, PharmD, BCGP

A recent study used MRI to show that tofacitinib reduces inflammation and inhibition of the progression of structural damage in adults with early RA…... [Read More]

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: Magnetic resonance imaging (MRI), Methotrexate, MRI, Rheumatoid Arthritis (RA), Tofacitinib

Rheumatology Drug Updates on Brentuximab Vedotin, Tofacitinib Citrate

November 17, 2015 • By Michele B. Kaufman, PharmD, BCGP

Brentuximab Vedotin Enters Phase 2 Trials Brentuximab vedotin (Adcetris), an antibody-drug conjugate (ADC) directed at CD30, is currently entering Phase 2 clinical trials for treating systemic lupus erythematosus (SLE).1 The ADC encompasses an anti-CD30 monoclonal antibody, which is attached by a protease-cleavable linker to a microtubule-disrupting agent, known as monomethyl auristatin E (MMAE). The ADC… [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Brentuximab vedotin, disease-modifying antirheumatic drug, DMARD, Drugs, FDA, hydroxyurea, MRI, rheumatology, Safety, tofacitinib citrate

Tofacitinib on Hold for Psoriasis, Plus Anti-TNFs Top FDA List for Adverse Events

October 28, 2015 • By Michele B. Kaufman, PharmD, BCGP

The FDA is asking for more safety analysis before approving tofacitinib to treat psoriasis. Also, adalimumab and etanercept received the greatest number of adverse and serious adverse events reported to the FDA in 2014…... [Read More]

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, adverse event, Anti-TNF, etanercept, FDA, Food and Drug Administration, Institute for Safe Medication Practices, plaque psoriasis, Tofacitinib, tofacitinib citrate

Tofacitinib Not Tied to More Malignancies in RA Patients

July 17, 2015 • By David Douglas

NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) does not increase the risk of malignancies, according to pooled data from more than 5000 rheumatoid arthritis (RA) patients. In an April 22 online paper in Annals of the Rheumatic Diseases, Dr. Lisy Wang of Pfizer, Groton, Connecticut, and colleagues noted that in RA… [Read More]

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: Cancer, malignancy, Rheumatiod arthritis, Tofacitinib

Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis

June 12, 2015 • By Reuters Staff

NEW YORK (Reuters Health)—Tofacitinib is better than placebo (and noninferior to etanercept) for treating patients with moderate-to-severe chronic plaque psoriasis, according to Pfizer’s OPT Compare trial. In an earlier 12-week, phase 2b, dose-ranging trial, the oral JAK inhibitor tofacitinib proved to be more effective than placebo for treating patients with moderate-to-severe plaque psoriasis. Based on… [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: etanercept, Pfizer Inc., plaque psoriasis, Tofacitinib

Tofacitinib and Other Kinase Inhibitors Offer New Approach to Treating Rheumatoid Arthritis

June 1, 2013 • By Deborah L. Parks, MD

Small molecule kinase inhibitors, such as JAK inhibitors, provide a novel route for rheumatic disease treatment—and may promote our understanding of the immune system’s complexities... [Read More]

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: JAK inhibitors, Kinase Inhibitors, RA, Rheumatic Disease, Rheumatoid arthritis, Tofacitinib, Treatment

Late-Breaking Abstract Session Spans the Realm of Drug-Related Research

January 25, 2021 • By Vanessa Caceres

In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.... [Read More]

Filed Under: ACR Convergence, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2020, diffuse cutaneous systemic sclerosis, giant cell arteritis (GCA), mavrilimumab, tocilizumab, Tofacitinib, VIG7734, Ziritaxestat

Interfering with Interferon: Experts Discuss IFN Signaling & IFN Inhibition Treatment Possibilities

January 25, 2021 • By Mary Beth Nierengarten

ACR Convergence 2020

NIH investigators describe key features and genetic causes of Mendelian interferonopathies, & treatment approaches that may indicate the efficacy of IFN inhibition. ... [Read More]

Filed Under: ACR Convergence, Conditions, Meeting Reports Tagged With: ACR Convergence 2020, interferon, JAK inhibitors, jakinib, signaling

Case Report: A Non-Tuberculous Mycobacterial Infection

January 20, 2021 • By Bradley Bohman, MD, & Jawad Bilal, MBBS

Tumor necrosis factor-α inhibitors (TNFi’s) have emerged as an integral part of therapeutic strategies for several rheumatic diseases. TNF-α is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis (RA), seronegative spondyloarthropathies and inflammatory bowel disease (IBD). It also plays a central role in the immune response to mycobacterial infection.  Many biologic agents, particularly… [Read More]

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: bacteria, case report, Infection, tumor necrosis factor inhibitor (TNFi)

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 13
  • Next Page »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.